The Claim
In adults with irritable bowel syndrome, the therapeutic effect of open-label placebo is not significantly different from that of double-blind placebo, with both groups achieving approximately 70% of participants reaching a clinically meaningful 50-point reduction in IBS Severity Scoring System scores.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with irritable bowel syndrome, both open-label and double-blind placebos led to a 70% rate of clinically meaningful symptom improvement, showing no difference in effectiveness based on whether patients knew they were receiving a placebo.
See the scientific wording
In adults with irritable bowel syndrome, the therapeutic effect of open-label placebo is not significantly different from that of double-blind placebo, with both groups showing approximately 70% of participants achieving a clinically meaningful 50-point reduction in IBS Severity Scoring System scores, suggesting that blinding may not be necessary for placebo efficacy in this condition.
When a person believes a treatment will help their gut, their brain sends signals that calm overactive nerves in the intestines and slow down abnormal movements, which reduces pain and discomfort.
What the research says
1 studyStudy: Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial
In people with IBS, taking pills that are clearly labeled as placebos worked just as well as taking the same pills without knowing they were placebos — about 7 in 10 people felt significantly better in both groups.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.